Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial
Lung Cancer. 1997;16(2-3):279 
A Phase II Trial of Preoperative Concurrent Radiation Therapy and Weekly Paclitaxel/Carboplatin for Patients with Locally Advanced Non–Small-Cell Lung Cancer
Clinical Lung Cancer. 2004;6(1):33-42
191 Phase II trial of paclitaxel and carboplatin as first line treatment in advanced non small cell lung-cancer (NSCLS)
Lung Cancer. 1997;18:51
P-22 Sequential chemotherapy of advanced non small cell lung cancer (NSCLC) with irinotecan plus delayed carboplatin followed by weekly paclitaxel. A phase II trial
Lung Cancer. 2003;41:S96
Paclitaxel 175 mg/m2 plus Carboplatin versus Paclitaxel 225 mg/m2 plus Carboplatin for Advanced Non–Small-Cell Lung Cancer (NSCLC)
Clinical Lung Cancer. 2000;1(3):177-178
A phase I/II trial of carboplatin and navelbine® in advanced non small cell lung cancer (NSCLC)
Lung Cancer. 1994;11:121
Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer
Lung Cancer. 1996;15(1):154
Commentary on “Pilot and Safety Trial of Carboplatin, Paclitaxel, and Thalidomide in Advanced Non–Small-Cell Lung Cancer”
Clinical Lung Cancer. 2000;2(1):55
Phase II randomized trial comparing high-dose cisplatin with moderate- dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer
Lung Cancer. 1994;11(3-4):340
Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer
Cancer Research and Treatment. 2011;43(1):19-23
